Clinical Trial Update: Pembrolizumab + Idelalisib for Lung Cancer Study [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 study evaluating pembrolizumab with idelalisib in non-small cell lung cancer (including metastatic disease) was terminated with results posted in 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Idelalisib (idelalisib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Asha Nayak | Conditions: Non Small Cell Lung Cancer, Metastasis | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-02-28